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INTRODUCTION
Globally, cervical cancer is the third most common
female cancer, with over 500,000 new cases diag-
nosed every year according to the WHO.1 More
than 85% of these cases and deaths occur in eco-
nomically developing and medically underserved
countries, largely in sub-Saharan Africa, South
America, and South-Central Asia, where it is often
the second most common female cancer. There are
still almost 300,000 deaths from this disease re-
corded annually.2
According to the staging of cervical cancer by the
International Federation of Gynecology and Obste-
trics (FIGO) in 2009, stage IIB is a locally advanced
stage of disease, characterized by tumor larger than
4 cm, with involvement of the upper b of the va-
Abstract
Objective: To evaluate the clinical efficacy, operability, radicality,
toxicity, and incidence of recurrences of neoadjuvant chemotherapy
(NAC) followed by radical hysterectomy (RH) among patients with
stage IIB cervical cancer.
Method: This is an observational clinical study at Dr. Moh. Hoesin
Hospital, Palembang. Data were analyzed from 27 patients who
matched the inclusion criteria and underwent 3 cycles of neoadju-
vant chemotherapy (NAC) with Paclitaxel (75 mg/m2) in combina-
tion with Cisplatin (50 mg/m2) and Docetaxel (75 mg/m2) combined
with Carboplatin (300 mg/m2) according to AUC 6, followed by radi-
cal hysterectomy from January 2012 until December 2013.
Result: The operability rate after NAC was 96.4%. Lymph node me-
tastases were negative in 75% of patients, and we found bilateral
lymph node metastases in 14.3% of patients. Parametric infiltrations
were negative in 85.7% of the patients, and positive in 14.3% of pa-
tients. No vaginal infiltrations were found. As much as 89.3% of the
patients did not experience any side effect, while anemia and throm-
bocytopenia were found in 10.8% of the patients. We found that
7.1% of patients had recurrences within 6 months interval.
Conclusion: NAC followed by radical hysterectomy showed signifi-
cant advantages for patients with stage IIB cervical cancer, with
fewer side effects. However, long-term evaluation and a larger num-
ber of patients are required to confirm this result.
[Indones J Obstet Gynecol 2015; 2: 106-109]
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Abstrak
Tujuan: Untuk mengetahui efikasi klinis, operabilitas, radikalitas, tok-
sisitas, dan angka rekurensi dari pemberian kemoterapi neoadjuvan
diikuti dengan histerektomi radikal pada pasien kanker serviks sta-
dium IIB.
Metode: Penelitian ini adalah penelitian observasional klinis yang di-
lakukan di RSUP Dr. Moh. Hoesin, Palembang. Data dianalisis dari 27
pasien yang memenuhi kriteria inklusi, dan menjalani kemoterapi
neoadjuvan dengan regimen Paclitaxel (75 mg/m2)-Cisplatin (50
mg/m2) dan Docetaxel (75 mg/m2)-Carboplatin (300 mg/m2) ber-
dasarkan AUC 6, sebanyak 3 siklus dilanjutkan dengan histerektomi
radikal dari Januari 2012 sampai Desember 2013.
Hasil: Angka operabilitas setelah dilakukan kemoterapi adjuvan adalah
96,4%. Pada 75% pasien tidak ditemukan metastasis ke kelenjar getah
bening, dan didapatkan metastasis ke kelenjar getah bening bilateral
pada 14,3% pasien. Tidak ditemukan infiltrasi parametrium pada 85,7%
pasien, dan ditemukan infiltrasi pada 14,3% pasien. Tidak ditemukan in-
filtrasi vagina pada seluruh pasien. Didapatkan efek samping berupa
anemia dan trombositopenia sebanyak 10,8%, sedangkan pada 89,3%
pasien tidak didapatkan efek samping. Sebanyak 7,1% pasien menga-
lami rekurensi dalam interval 6 bulan setelah pembedahan.
Kesimpulan: Kemoterapi neoadjuvan diikuti dengan histerektomi ra-
dikal memberikan manfaat yang signifikan pada pasien kanker serviks
stadium IIB. Namun, untuk mengkonfirmasi hasil dari penelitian ini
dibutuhkan evaluasi jangka panjang dan jumlah sampel yang lebih be-
sar.
[Maj Obstet Ginekol Indones 2015; 2: 106-109]
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gina, bilateral or unilateral parametrial involve-
ment without extension to the pelvic sidewall.3
Currently, there is no international agreement on
how FIGO stage IIB patients should be treated. The
National Comprehensive Cancer Network (NCCN)
guidelines recommend cisplatin-based chemora-
diotherapy as a primary treatment for FIGO stage
IIB disease. More recently, several opinions have
been voiced on the efficacy of neoadjuvant chemo-
therapy (NAC) followed by surgery compared to
concomitant radiotherapy and chemotherapy in
patients with FIGO IIB cervical cancer.3-5
In this study, we aim to evaluate the clinical ef-
ficacy, toxicity, and recurrences of neoadjuvant
chemotherapy followed by radical hysterectomy
(RH) among patients with cervical cancer stage IIB.
METHODS
This is an observational clinical study at Dr. Moh.
Hoesin Hospital, Palembang, Indonesia. Data were
analyzed from 28 patients with stage IIB cervical
cancer who underwent treatment between January
2012 and December 2013. Approval was provided
by the Research Ethics Committee.
Patients were evaluated by board-certified gy-
necologic oncologists. The evaluation consists of
physical examination, transvaginal ultrasonogra-
phy, and thoracic radiography. Intravenous pyelo-
graphy, magnetic resonance imaging, and compu-
ted tomography were performed as considered ap-
propriate.
The inclusion criteria were all patients who un-
derwent neoadjuvant chemotherapy for 3 cycles
followed by type III radical hysterectomy, unless it
was contraindicated, as determined by physical
examination. The regimens of NAC were cisplatin-
paclitaxel, and docetaxel-carboplatin with a three
weekly interval. The exclusion criteria were pa-
tients who received more than 3 cycles of NAC, and
refused to undergo radical hysterectomy.
Periodic follow-up of patients included post-
operative adjuvant therapy, physical examination,
vaginal cytology, and imaging such as thoracic ra-
diography, computed tomography, or magnetic re-
sonance imaging continued until March 2014. All
data from the patients were recorded and analyzed
using SPSS version 18.0.
RESULTS
During the study period, 28 patients with stage IIB
cervical cancer were treated in Dr. Moh. Hoesin
Palembang, Indonesia. All of them received 3 series
of NAC with the regimen Docetaxel-Carboplatin
and Paclitaxel-Cisplatin. The kinds of regimen the
patients received are detailed in Table 1. Twenty-
seven of them then underwent radical hysterec-
tomy. As many as 26 patients (92.9%) underwent
type II radical hysterectomy, and one of them
(3.6%) underwent type I radical hysterectomy.
The age of the patients ranged from 29 to 59
years old. The majority of our patients had squa-
mous cell carcinoma of the cervix (82.1%). The
clinical features of our patients before NAC and the
type of histopathology are summarized in Table 2.
After being treated with NAC, the patients were
evaluated; and 27 of them were assessed as oper-
able and underwent radical hysterectomy. One of
them was found to be inoperable.
The toxicities associated with NAC were pre-
dominantly grade 1 and grade 2, including bone
marrow suppression with leukopenia, thrombocy-
topenia, and a decrease in hemoglobin, which were
in 3.6% of the patients for each group. No grade 3
and 4 toxicities were observed.
Metastasis was evaluated according to the pa-
thologic data reported from surgical specimens in-
cluding lymph nodes metastasis, positive surgical
margin, and parametric infiltration. Positive surgi-
cal margin was found in one patient (3.6%) and 26
patients did not have infiltration in the surgical
margins. Four of the patiens (14.3%) showed para-
metric infiltration. Four patients (14.3%) showed
bilateral lymph node metastases, and 2 patients
showed unilateral lymph nodes metastases. The
clinical features of our patients after surgery are
presented in Table 3.
Table 1. Main Regimens of NAC
Regimen
Number of Patients Based on Histopathologic Types
Squamous Adenocarcinoma Clear cell
Docetaxel - Carboplatin 2
Paclitaxel - Cisplatin 21 4 1
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Table 2. Clinical Features of the Study Subjects (n=28)
n (%)
Age
29-39 4 (14.3%)
40-49 14 (50%)
50-59 10 (35.7%)
Tumor diameter, cm
≤ 4 cm 17 (60.7%)
>4 cm 11 (39.3%)
Histology
Squamous 23 (82.1%)
Adenocarcinoma 4 (14.3%)
Clear cell 1 (3.6%)
Cancer free space (CFS)
25% 3 (10.7%)
50% 13 (46.4%)
75% 4 (14.3%)
100% 8 (28.6%)
Operability
Operable 27 (96.4%)
Not operable 1 (3.6%)
Type of hysterectomy
Type II 1 (3.6%)
Type III 26 (92.9%)
Not performed 1 (3.6%)
Toxicities
Grade I 1 (3.6%)
Grade II 1 (3.6%)
None 26 (92.8%)
Table 3. Clinical Features after Radical Hysterectomy
n (%)
Positive lymph nodes
Bilateral 4 (14.3%)
Unilateral 2 (7.1%)
Negative 21 (75%)
Unknown 1 (3.6%)
Parametrial invasion
Positive 4 (14.3%)
Negative 23 (82.1%)
Unknown 1 (3.6%)
Surgical margin
Positive 1 (3.6%)
Negative 26 (92.8%)
Unknown 1 (3.6%)
Local recurrence to the vagina after 6 months
was observed in two patients, and 26 patients
showed no incidence of recurrence. Until May
2014, the survival rate of the patients showed that
27 of the patients (96.4%) were still alive with no
progression of disesase, while one patient (3.6%)
died due to disease complication.
Table 4. Treatment Outcome
n (%)
Local recurrence after 6 months
Positive 2 (7.2%)
Negative 26 (92.8%)
Death
Positive 1 (3.6%)
Negative 27 (96.4%)
DISCUSSION
Neoadjuvant chemotherapy is widely used in stage
IIB cervical cancer patients. In this study all pa-
tients were given three cycles of intravenous NAC
with three weekly intervals. This method is con-
venient and does not require any special equip-
ment. In this study, NAC showed greater clinical
values.4,6,7
It remains controversial as to whether NAC con-
fers any clinical benefits in the treatment of cervical
cancer. In a phase III trial in stage IB2 cervical can-
cer comparing NAC followed by surgery with sur-
gery alone. Eddy et al reported similar recurrence
rates and death rates between the two groups, and
no evidence that NAC conferred any additional ob-
jective benefits.7 Nevertheless, NAC continues to be
used as it may contribute to ease surgical interven-
tion by reducing tumor size. It may also be useful
as a preliminary treatment while the patient is on
a waiting list for surgery.8-10 Matsumura et al
showed an average of 1.4 courses of NAC with as
many as 58.7% (27/46) of the patients receiving
only one cycle of NAC, suggesting that the benefit
conferred was that of tumor reduction rather than
survival benefit.11 Platinum-based chemotherapy
was considered the most effective regimen in che-
motherapy for cervical cancer. Sugiyama et al re-
ported a 78% response rate for this combination
in NAC for cervical cancer.12
The few studies using NAC (platinum-based) to
treat cervical cancer have reported a response rate
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of 66.6% to 94%. In this study, after receiving 3
cycles of NAC prior to radical hysterectomy, we
found that 96.4% of patients were operable, and
only one patient was not operable. Grade 1 and
grade 2 toxicities were found in 3.6% of patients
in both groups. Positive surgical margins were
found in one patient (3.6%). Whereas, four of the
patients (14.3%) showed parametric infiltration,
14,3% of patients showed bilateral lymph nodes
metastases, and two of them showed unilateral
lymph node metastases. Local recurrence to the va-
gina after 6 months was found in two patients. The
survival rate of the patients showed that 27 of the
patients (96.4%) were still alive with no progres-
sion of disease after 6 months, while one of the pa-
tients (3,6%) died due to disease complication.
CONCLUSION
In summary, the results of the current study indi-
cate that NAC followed by radical hysterectomy is
a viable option in the treatment of stage IIB cervical
cancer. This treatment may allow avoidance of the
long-term toxicities that can arise from radiothe-
rapy and chemotherapy alone. NAC appears to of-
fer an advantage in terms of tumor reduction prior
to surgical intervention, with mild toxicity.
Further studies are needed, with a bigger sample
size in a multicenter randomized clinical trial set-
ting, and with longer duration of follow up.
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